Omicron may challenge vaccine protection more than other variants, early lab data suggests, but the shots could still protect against severe disease




  • In Science
  • 2021-12-07 22:45:41Z
  • By Business Insider
omicron airport
omicron airport  
  • Pfizer's COVID-19 vaccine may yield substantially fewer antibodies against the Omicron variant.

  • One study found the vaccine showed a 40-fold reduction in antibody levels in a study awaiting peer review.

  • Breakthrough infections still appear to be mild.

The Omicron variant substantially reduced antibody levels generated by the Pfizer-BioNTech COVID-19 vaccine, according to preliminary results from a South African study that's still awaiting peer review.

These are the first laboratory results to see how a COVID-19 vaccine holds up to Omicron. A team of researchers led by Africa Health Research Institute's Alex Sigal tested 14 blood samples from 12 people against a live sample of the Omicron variant. All 12 people were vaccinated, and six were previously infected.

Overall, the scientists found a roughly 40-fold reduction in the levels of neutralizing antibodies, the virus-fighting proteins that play a key role in our immune response, compared with the original version of the virus.

Omicron did not evade vaccine protection completely, Sigal wrote on Twitter, meaning there's still benefit to being vaccinated against this new variant. But the marked reduction in antibodies raises questions of how durable vaccine protection will be against Omicron - namely, whether booster shots will sufficiently ward off disease or if new vaccines may eventually be required. Sigal called it a "very large drop in neutralization of Omicron."

"A good booster probably would decrease your chance of infection, especially severe infection leading to more severe disease," Sigal said in an online presentation of his results on Tuesday, according to Bloomberg. "People who haven't had a booster should get one, and people who have been previously infected should be vaccinated."

Shortly after Sigal announced his team's results, another group of researchers at Sweden's Karolinska Institutet disclosed their own findings that suggested a substantial but less dramatic decline in antibody levels. The Karolinska team found a seven-fold reduction across 17 blood samples.

They noted the impact of Omicron varied greatly between samples, and they used a version of Omicron that was artificially made in a lab instead of the live virus. A lead researcher for that group said the findings make Omicron "certainly worse than Delta, but, again, not as extreme as we expected."

Other variants have also shown the ability to partially evade the vaccine's protection to a lesser degree. Previous lab tests showed the Delta variant led to a 2- to 3-fold reduction in antibodies compared with the original virus, while the Beta variant caused a 7- to 8-fold reduction.

The results are not finalized and have not been published in a medical journal. Sigal cautioned on Twitter that the findings "are likely to be adjusted as we do more experiments."

Drugmakers are working on variant-specific boosters

A New York woman receives a Pfizer COVID-19 vaccination.
A New York woman receives a Pfizer COVID-19 vaccination.  

Pfizer Chief Scientific Officer Mikael Dolsten previously told Insider he'd be worried to see a 10-fold reduction in antibody levels. A decrease of that magnitude, he said, would make him concerned that current vaccines wouldn't offer sufficient protection and an Omicron-specific shot would be needed.

"If we exceed a 10-fold drop in neutralization of Omicron, I think we are starting to enter the yellow to red zone, when your immunity is likely lowered and there's limited time after your boost until waning," Dolsten said in a November 29 interview.

Several vaccine developers, including Pfizer, Moderna, and Johnson & Johnson, are already working on Omicron-specific shots. Dolsten said an updated version could be ready to start mass-producing as soon as March 2022.

The South African study only analyzed blood samples from people who got two shots of Pfizer's vaccine, not people who'd received a booster shot. Five of the six blood samples that came from people who were both vaccinated and previously infected showed relatively high levels of neutralizing antibodies against Omicron.

"Previous infection, followed by vaccination or booster is likely to increase the neutralization level and likely confer protection from severe disease in Omicron infection," the researchers wrote.

Even reduced antibody levels may still protect against severe disease

south africa omicron testing
south africa omicron testing  

It's still unclear if Omicron will impact vaccine protection against severe disease.

Virologists are cautiously optimistic that the vaccines could still help prevent critical illness, despite significant drops in antibody levels. Vaccines also activate other parts of the immune system, particularly B- and T-cells that often confer protection against variants.

Anecdotally, disease experts in South Africa have suggested that vaccines still seem to reduce the risk of serious illness among Omicron cases.

"We are seeing breakthrough infections of people who have been vaccinated, but the infections we're seeing are very mild to moderate," Richard Friedland, chief executive officer of Netcare, which operates South Africa's largest private healthcare network, told Bloomberg on Friday. He added that "for healthcare workers who have had boosters, it's mostly mild."

But Omicron has also shown signs of being highly transmissible compared with other coronavirus strains. The variant has spread to more than 40 countries since it was first detected roughly a month ago.

COMMENTS

More Related News

When should I get a COVID booster? Next-generation antibody tests could help.
When should I get a COVID booster? Next-generation antibody tests could help.

Scientists are working on COVID antibody tests to help people know when their own protection is fading and a booster may be needed.

Pfizer CEO tests positive for COVID-19, experiencing
Pfizer CEO tests positive for COVID-19, experiencing 'very mild symptoms'

Albert Bourla said he has received four doses of the Pfizer-BioNTech vaccine and started a course of Paxlovid after testing positive for COVID-19.

Pfizer CEO tests positive for COVID-19, has mild symptoms
Pfizer CEO tests positive for COVID-19, has mild symptoms

The top executive at Pfizer, a leading producer of COVID-19 vaccines, has tested positive for the virus and says he is experiencing very mild symptoms. Chairman and CEO Albert Bourla said Monday that he started taking Pfizer's Paxlovid pill treatment and is isolating while he recovers. Bourla has received four shots of Comirnaty, the COVID-19 vaccine developed by the New York drugmaker along with BioNTech.

Factbox - Latest on the worldwide spread of the coronavirus
Factbox - Latest on the worldwide spread of the coronavirus
  • US
  • 2022-08-15 13:48:20Z

* About 2.3 million people in the Philippines were pushed into poverty between 2018 and 2021, rising to a total of almost 20 million, or 18.1% of the...

UPDATE 5-UK first to approve Omicron COVID shot with Moderna nod
UPDATE 5-UK first to approve Omicron COVID shot with Moderna nod

Britain, the first country to approve a coronavirus vaccine in late 2020, has now also given the first green light to a variant-adapted shot that targets...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

  • discuss
    (2021-12-08 20:11:55Z)

    If some one wants expert view on the topic of blogging and site-building
    after that i advise him/her to pay a quick visit this webpage,
    Keep up the good work.

    REPLY

Top News: Science